10-Q: Palisade Bio Reports Q1 2025 Financial Results, Highlights PALI-2108 Clinical Trial Progress

Palisade Bio announces its Q1 2025 financial results, showcasing a decrease in net loss and providing updates on the clinical development of its lead product candidate, PALI-2108.

Summary

• Palisade Bio, a clinical-stage biopharmaceutical company, reported a net loss of $2.23 million for the three months ended March 31, 2025, compared to a net loss of $3.53 million for the same period in 2024.
• Research and development expenses decreased by 57% to $950,000, primarily due to reduced preclinical joint development expenses related to PALI-2108.
• General and administrative expenses decreased by 7% to $1.36 million.
• As of March 31, 2025, the company had cash and cash equivalents of $7.23 million.
• The company expects to announce topline data from the Phase 1 clinical study of PALI-2108 in the second quarter of 2025.
• Based on the company's current working capital, anticipated operating expenses, and anticipated net operating losses, there is substantial doubt about the company's ability to continue as a going concern for a period of one year following the date that these condensed consolidated financial statements are issued.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company has reduced its net loss and is progressing with its clinical trial, there are significant concerns about its financial stability and ability to continue as a going concern. The presence of a material weakness in internal controls and the potential for delisting from Nasdaq further contribute to the negative sentiment.

Positives

• The company's net loss decreased significantly compared to the same period last year.
• Research and development expenses decreased, indicating improved efficiency or a shift in focus.
• The company is progressing with the Phase 1 clinical trial of PALI-2108 and expects topline data soon.
• The company has two qualified suppliers for the active pharmaceutical ingredient used in the clinical trials of PALI-2108.

Negatives

• The company has a limited operating history and has never generated any revenues from product sales.
• The company has a history of net operating losses, and expects to continue to incur net operating losses and may never achieve profitability.
• The company has expressed substantial doubt about its ability to continue as a going concern.
• The company has identified a material weakness in its internal controls over financial reporting.
• The company's common stock could be delisted from the Nasdaq Stock Market if it is unable to maintain compliance with the Nasdaq Stock Market's continued listing standards.

Risks

• The company's business depends on the successful clinical development, regulatory approval, and commercialization of its therapeutic compounds, including its lead asset PALI-2108.
• There are substantial risks in drug development, and, as a result, the company may not be able to successfully develop any product candidate, including its lead product candidate, PALI-2108.
• The company depends on its license agreement with Giiant Pharma Inc. ('Giiant') to permit it to use patents and patent applications relating to PALI-2108.
• The company is currently conducting a Phase 1 clinical trial of PALI-2108 in Canada, and the U.S. Food and Drug Administration (FDA) or applicable foreign regulatory authorities may not accept data from such trials, or any other trial the company conducts outside of the U.S.
• The company may find it difficult to enroll patients in its clinical trials, which could delay or prevent the company from proceeding with clinical trials of its product candidates.
• The company expects that its operations and development of PALI-2108 will require substantially more capital than it currently has, and the company cannot guarantee when or if it will be able to secure such additional funding.
• The company's product candidates, including its lead product candidate PALI-2108, may cause undesirable side effects or have other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in post-approval regulatory action.
• There can be no assurance that the company's product candidates will obtain regulatory approval.
• If clinical studies of PALI-2108 do not yield successful results, the company may discontinue the development of PALI-2108.
• It may take the company longer than it estimates to complete clinical trials, and the company may not be able to complete them at all.
• Even if PALI-2108 is approved for commercialization, future regulatory reviews or inspections may result in its suspension or withdrawal, closure of a facility or substantial fines.
• The successful commercialization of PALI-2108, if approved, will depend in part on the extent to which government authorities and health insurers establish adequate reimbursement levels and pricing policies.
• The company faces potential product liability exposure, and if successful claims are brought against it, it may incur substantial liability for a product candidate and it may need to limit its commercialization.
• Even if a product candidate obtains regulatory approval, it may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success.

Future Outlook

The company anticipates announcing topline data from the Phase 1 clinical study of PALI-2108 during the second quarter of 2025 and plans to initiate a Phase 1b/2a clinical study in UC patients and FSCD patients in the first quarter of 2026, assuming the Phase 1 trial meets its primary objectives.

Management Comments

• Management has determined that there is substantial doubt about the company's ability to continue as a going concern for a period of one year following the issuance of this Quarterly Report on Form 10-Q.

Industry Context

Palisade Bio is operating in the competitive biopharmaceutical industry, focusing on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, specifically targeting inflammatory bowel disease (IBD). The company's lead product candidate, PALI-2108, is being developed as a treatment for patients living with IBD, including fibrostenotic Crohn's disease and ulcerative colitis. The company's approach involves the use of clinical and multiomics data from large patient populations to identify PDE4-related biomarkers that are correlated with IBD, its severity, and which are modified with local PDE4-inhibitor therapy in the colon.

Comparison to Industry Standards

• It is difficult to compare Palisade Bio's results directly to industry standards due to its early stage of development and specific focus on PALI-2108.
• However, similar companies in the biopharmaceutical industry, such as Viking Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc., are also focused on developing novel therapeutics for various diseases.
• Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.
• Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for non-alcoholic steatohepatitis (NASH) and other liver diseases.
• These companies, like Palisade Bio, face the challenges of clinical development, regulatory approval, and commercialization.
• Palisade Bio's cash position of $7.23 million is relatively low compared to some of its peers, which may limit its ability to fund its clinical development programs.
• However, the company's reduced net loss and research and development expenses may indicate improved efficiency and a focus on its lead product candidate.

Corporate Governance

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential loss of investment due to the company's financial instability.
• Employees may be affected by potential workforce reductions or delays in compensation due to the company's financial challenges.
• Customers (potential patients) may experience delays in the development and availability of new treatments due to the company's financial constraints.
• Suppliers and creditors may face increased risk of non-payment or delayed payments due to the company's financial instability.

Next Steps

• The company expects to announce topline data from the Phase 1 clinical study of PALI-2108 in the second quarter of 2025.
• The company plans to initiate a Phase 1b/2a clinical study in UC patients and FSCD patients in the first quarter of 2026, assuming the Phase 1 trial meets its primary objectives.
• The company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options to regain compliance with the Bid Price Rule.

Key Dates

Keywords

PALI-2108, inflammatory bowel disease, IBD, clinical trial, biopharmaceutical, research and development, financial results, Palisade Bio